Dataset Information

Post-COVID-19 functional status: Relation to age, smoking, hospitalization, and previous comorbidities.

ABSTRACT:

Rational

Recently, a new "Post-COVID-19 Functional Status (PCFS) scale" is recommended in the current COVID-19 pandemic. It is proposed that it could be used to display direct retrieval and the functional sequelae of COVID-19.

Aim of the study

The aim of the study was to assess the PCFS and to evaluate if age, gender, smoking, hospitalization, and comorbidities have any effect on functional limitations in recovered COVID-19 patients.

Methods

A total of 444 registered confirmed COVID-19 patients were included. They were interviewed in our follow-up clinics and filled an Arabic translated PCFS scale as well as their demographic and clinical data.

Results

Eighty percent of COVID-19 recovered cases have diverse degrees of functional restrictions ranging from negligible (63.1%), slight (14.4%), moderate (2%), to severe (0.5%) based on PCFS. Furthermore, there was a substantial variance between the score of PCFS with age (P = 0.003), gender (P = 0.014), the duration since the onset of the symptoms of COVID-19 (P < 0.001), need for oxygen supplementation (P < 0.001), need for intensive care unit (ICU) admittance (P = 0.003), previous periodic influenza vaccination (P < 0.001), smoking status (P < 0.001), and finally, the presence of any comorbid disorder (P < 0.001).

Conclusions

Most of the COVID-19 recovered cases have diverse degrees of functional restrictions ranging from negligible to severe based on PCFS. These restrictions were affected by age, gender, periodic influenza vaccination, smoking, duration since symptoms onset, need for oxygen or ICU admittance, and finally the presence of coexisting comorbidity.

SUBMITTER: Mohamed Hussein AA

PROVIDER: S-EPMC8388571 | biostudies-literature | 2021 Jul-Sep

REPOSITORIES: biostudies-literature

ACCESS DATA

Publications

Post-COVID-19 functional status: Relation to age, smoking, hospitalization, and previous comorbidities.

Mohamed Hussein Aliae Ar AA Saad Mahmoud M Zayan Hossam E HE Abdelsayed Mustafa M Moustafa Mohamed M Ezzat Abdel Rahman AR Helmy Radwa R Abd-Elaal Howaida H Aly Karim K Abdelrheem Shaimaa S Sayed Islam I

Annals of thoracic medicine 20210720 3

<h4>Rational</h4>Recently, a new "Post-COVID-19 Functional Status (PCFS) scale" is recommended in the current COVID-19 pandemic. It is proposed that it could be used to display direct retrieval and the functional sequelae of COVID-19.<h4>Aim of the study</h4>The aim of the study was to assess the PCFS and to evaluate if age, gender, smoking, hospitalization, and comorbidities have any effect on functional limitations in recovered COVID-19 patients.<h4>Methods</h4>A total of 444 registered confir ...[more]

PMID: 34484441

Similar Datasets

Project description:IntroductionSmoking history is a known risk factor for significant chronic diseases as well as pulmonary infections; however, the impact of smoking status on COVID-19 outcomes has not been conclusively characterized. This study aims to evaluate the association of smoking status on COVID-19 outcomes, and to explore the mechanism by which smoking and smoking-related comorbidities relate to COVID-19 outcomes.MethodsPatients admitted with SARS-CoV-2 infection from November 2020 through January 2021 were included in this study. Causal mediation models investigating the associations between smoking status and the outcomes of mortality, intensive care unit (ICU) admission, advanced respiratory support, mechanical ventilation, ICU length of stay, and hospital length of stay, through mediation via smoking-related comorbidities, were examined.ResultsActive smokers did not experience worse COVID-19 outcomes once hospitalized. Former smokers had a higher odds of mortality (total effect OR 1.59, 95% CI 1.07-2.38, p=.01; indirect effect OR 1.45, 95% CI 1.09-1.93, p<.001), and advanced respiratory support (total effect OR 1.31, 95% CI 1.04-1.67, p=.02; indirect effect OR 1.26, 95% C1.03-1.54, p=.02), which were mediated by smoking-related comorbidities. While there was a non-significant increase in the total effect for mechanical ventilation, smoking-related comorbidities were significant mediators for their increased need (total effect OR 1.40, 95% CI 0.92-2.14, p=.13; indirect effect OR 1.47, 95% CI 1.10-1.87, p<.001).ConclusionWhile active smokers did not experience worse COVID-19 outcomes compared to never smokers, these results should be interpreted with caution. Compared to never smokers, former smokers had greater odds of mortality, advanced respiratory support, and mechanical ventilation which was significantly mediated through smoking-related comorbidities.ImplicationsPrevious studies have linked smoking status with worse COVID-19 outcomes, and have inferred that smoking-related comorbidities may play a role in these findings. This causal mediation analysis provides statistical evidence supporting this hypothesis, clarifying the risk that smoking-related comorbidities impart on COVID-19 outcomes in those with a smoking history.

Project description:BackgroundThe successful development of multiple COVID-19 vaccines has led to a global vaccination effort to reduce severe COVID-19 infection and mortality. However, the effectiveness of the COVID-19 vaccines wane over time leading to breakthrough infections where vaccinated individuals experience a COVID-19 infection. Here we estimate the risks of breakthrough infection and subsequent hospitalization in individuals with common comorbidities who had completed an initial vaccination series.MethodsOur study population included vaccinated patients between January 1, 2021 to March 31, 2022 who are present in the Truveta patient population. Models were developed to describe 1) time from completing primary vaccination series till breakthrough infection; and 2) if a patient was hospitalized within 14 days of breakthrough infection. We adjusted for age, race, ethnicity, sex, and year-month of vaccination.ResultsOf 1,218,630 patients in the Truveta Platform who had completed an initial vaccination sequence between January 1, 2021 and March 31, 2022, 2.85, 3.42, 2.75, and 2.88 percent of patients with CKD, chronic lung disease, diabetes, or are in an immunocompromised state experienced breakthrough infection, respectively, compared to 1.46 percent of the population without any of these four comorbidities. We found an increased risk of breakthrough infection and subsequent hospitalization in individuals with any of the four comorbidities when compared to individuals without these four comorbidities.ConclusionsVaccinated individuals with any of the studied comorbidities experienced an increased risk of breakthrough COVID-19 infection and subsequent hospitalizations compared to the people without any of the studied comorbidities. Individuals with immunocompromising conditions and chronic lung disease were most at risk of breakthrough infection, while people with CKD were most at risk of hospitalization following breakthrough infection. Patients with multiple comorbidities have an even greater risk of breakthrough infection or hospitalization compared to patients with none of the studied comorbidities. Individuals with common comorbidities should remain vigilant against infection even if vaccinated.

Dataset Information

Post-COVID-19 functional status: Relation to age, smoking, hospitalization, and previous comorbidities.

Rational

Aim of the study

Methods

Results

Conclusions

Publications

Post-COVID-19 functional status: Relation to age, smoking, hospitalization, and previous comorbidities.

Similar Datasets

OmicsDI is part of the ELIXIR infrastructure

Tweets